GSK to acquire cancer therapeutics company Tesaro for $5.1bn in cash
GlaxoSmithKline PLC agreed to acquire Tesaro Inc. (cancer biopharma) for $75 per share (76% premium to the prior 10-day trading average) in cash, or an enterprise value of $5.1bn.
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com